Quick Answer
Rapport Therapeutics, Inc. reported Shares Outstanding of 47.77 million shares for fiscal year 2025.
Rapport Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 47.77M | +30.6% |
| 2024 | 36.58M | +777.1% |
| 2023 | 4.17M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 47.65M | +30.3% | +30.6% |
| June 30, 2025 | 36.50M | -0.2% | +0.0% |
| March 31, 2025 | 36.50M | — | -0.2% |
| December 31, 2024 | 36.58M | +777.1% | +0.0% |
| September 30, 2024 | 36.58M | — | +0.0% |
| June 30, 2024 | 36.58M | — | +777.0% |
| December 31, 2023 | 4.17M | — | — |
- Rapport Therapeutics, Inc. showed an increase of +30.6% in Shares Outstanding compared to the prior fiscal year.
- Over the 2023–2025 period, Rapport Therapeutics, Inc.’s shares outstanding has grown by 1045.4% (from 4.17 million shares to 47.77 million shares).
- The most recent figure is from Rapport Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: